دورية أكاديمية
أعرض في EDS

25-Hydroxyvitamin D and TSH as Risk Factors or Prognostic Markers in Thyroid Carcinoma.

التفاصيل البيبلوغرافية
العنوان: 25-Hydroxyvitamin D and TSH as Risk Factors or Prognostic Markers in Thyroid Carcinoma.
المؤلفون: Danilovic DL; Endocrinology, Instituto do Câncer do Estado de São Paulo, Sao Paulo, Brazil.; Laboratório de Endocrinologia Celular e Molecular (LIM25), Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil., Ferraz-de-Souza B; Laboratório de Investigação Médica 18 (LIM-18), Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil., Fabri AW; Laboratório de Endocrinologia Celular e Molecular (LIM25), Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil., Santana NO; Laboratório de Endocrinologia Celular e Molecular (LIM25), Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil., Kulcsar MA; Head and Neck Surgery, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil., Cernea CR; Head and Neck Surgery, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil., Marui S; Laboratório de Endocrinologia Celular e Molecular (LIM25), Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil., Hoff AO; Endocrinology, Instituto do Câncer do Estado de São Paulo, Sao Paulo, Brazil.
المصدر: PloS one [PLoS One] 2016 Oct 13; Vol. 11 (10), pp. e0164550. Date of Electronic Publication: 2016 Oct 13 (Print Publication: 2016).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: Carcinoma/*pathology , Thyroid Neoplasms/*pathology , Thyrotropin/*metabolism , Vitamin D/*analogs & derivatives , Vitamin D Deficiency/*epidemiology, Adult ; Aged ; Carcinoma/metabolism ; Carcinoma, Papillary ; Cross-Sectional Studies ; Female ; Humans ; Lymphatic Metastasis ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Risk Factors ; Thyroid Cancer, Papillary ; Thyroid Neoplasms/metabolism ; Vitamin D/metabolism
مستخلص: Objective: The increasing incidence of thyroid nodules demands identification of risk factors for malignant disease. Several studies suggested the association of higher TSH levels with cancer, but influence of 25-hydroxyvitamin D (25OHD) is controversial. This study aimed to identify the relationship of thyroid cancer with higher TSH levels and hypovitaminosis D and to evaluate their influence on prognostic characteristics of papillary thyroid carcinomas (PTC).
Methods: We retrospectively evaluated 433 patients submitted to thyroidectomy for thyroid nodules. Patients were categorized according to quartiles of TSH and 25OHD levels. Clinicopathological features were analyzed.
Results: Subjects with thyroid carcinomas were more frequently male and younger compared to those with benign disease. Their median TSH levels were higher and adjusted odds-ratio (OR) for cancer in the highest-quartile of TSH (> 2.4 mUI/mL) was 2.36 (1.36-4.09). Although vitamin D deficiency/insufficiency was prevalent in our cohort (84%), no significant differences in 25OHD levels or quartile distribution were observed between benign and malignant cases. Among 187 patients with PTC, analyses of prognostic features revealed increased risk of lymph nodes metastases for subjects with highest-quartile TSH levels (OR = 3.7, p = 0.029). Decreased 25OHD levels were not overtly associated with poor prognosis in PTC.
Conclusions: In this cross-sectional cohort, higher TSH levels increased the risk of cancer in thyroid nodules and influenced its prognosis, particularly favoring lymph nodes metastases. On the other hand, no association was found between 25OHD levels and thyroid carcinoma risk or prognosis, suggesting that serum 25OHD determination may not contribute to risk assessment workup of thyroid nodules.
Competing Interests: The authors have declared that no competing interests exist.
References: Thyroid. 2013 Sep;23(9):1079-86. (PMID: 23350941)
Med Oncol. 2013;30(2):589. (PMID: 23645546)
Exp Clin Endocrinol Diabetes. 2015 Jul;123(7):386-93. (PMID: 26171622)
J Cell Biol. 2001 Jul 23;154(2):369-87. (PMID: 11470825)
J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):127-30. (PMID: 15225759)
Cancer. 2014 Feb 15;120(4):521-9. (PMID: 24166051)
PLoS One. 2014 Dec 01;9(12):e112863. (PMID: 25437008)
Int J Cancer. 2004 Jan 1;108(1):104-8. (PMID: 14618623)
Breast Care (Basel). 2010;5(6):383-387. (PMID: 21494403)
J Steroid Biochem Mol Biol. 2008 Sep;111(3-5):195-9. (PMID: 18590821)
Endocr Relat Cancer. 2013 Mar 22;20(2):R31-47. (PMID: 23319494)
Am J Clin Nutr. 2008 Apr;87(4):1080S-6S. (PMID: 18400738)
Endocr Relat Cancer. 2016 Apr;23 (4):251-64. (PMID: 26817629)
J Otolaryngol Head Neck Surg. 2012 Jun 1;41(3):160-3. (PMID: 22762696)
J Natl Cancer Inst. 2008 Nov 19;100(22):1581-91. (PMID: 19001601)
Endocr Relat Cancer. 2014 Oct;21(5):715-21. (PMID: 25030993)
Thyroid. 2013 Jan;23(1):25-30. (PMID: 22931506)
Cancer Prev Res (Phila). 2011 May;4(5):735-43. (PMID: 21430073)
Anticancer Res. 2012 Mar;32(3):727-31. (PMID: 22399584)
J Clin Endocrinol Metab. 2012 Aug;97(8):2682-92. (PMID: 22622023)
Thyroid. 2011 Mar;21(3):231-6. (PMID: 21268762)
PLoS One. 2014 Oct 20;9(10):e110886. (PMID: 25329812)
Br J Cancer. 1998 Apr;77(7):1174-9. (PMID: 9569058)
J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30. (PMID: 21646368)
J Steroid Biochem Mol Biol. 2016 May;159:26-30. (PMID: 26907966)
Int J Endocrinol. 2014;2014:841248. (PMID: 25161666)
Endocr Relat Cancer. 2012 May 03;19(3):R51-71. (PMID: 22383428)
Endocrine. 2011 Jun;39(3):259-65. (PMID: 21161440)
Endocrinology. 1993 May;132(5):1952-60. (PMID: 7682937)
PLoS One. 2010 Nov 09;5(11):e13882. (PMID: 21085485)
PLoS Med. 2013;10(2):e1001383. (PMID: 23393431)
Nat Rev Cancer. 2014 May;14 (5):342-57. (PMID: 24705652)
Clin Endocrinol (Oxf). 2009 Sep;71(3):434-9. (PMID: 19067720)
Thyroid. 2016 Jan;26(1):1-133. (PMID: 26462967)
Lancet. 1989 Nov 18;2(8673):1176-8. (PMID: 2572900)
J Clin Endocrinol Metab. 2011 Jan;96(1):53-8. (PMID: 21118827)
Medicine (Baltimore). 2013 May;92(3):123-31. (PMID: 23625163)
Ann Surg Oncol. 2012 Aug;19(8):2590-9. (PMID: 22446898)
Biochem Biophys Res Commun. 1996 Jun 5;223(1):141-6. (PMID: 8660360)
Clin Endocrinol (Oxf). 2006 Nov;65(5):660-6. (PMID: 17054470)
Clin Nutr. 2010 Dec;29(6):784-8. (PMID: 20637530)
Endocr Relat Cancer. 2009 Dec;16(4):1251-60. (PMID: 19528244)
Arch Med Res. 2010 Apr;41(3):190-4. (PMID: 20682176)
Osteoporos Int. 2009 Nov;20(11):1807-20. (PMID: 19543765)
J Clin Endocrinol Metab. 2014 Jul;99(7):2327-36. (PMID: 24780061)
Proc Natl Acad Sci U S A. 1981 Aug;78(8):4990-4. (PMID: 6946446)
Mol Cancer Ther. 2007 Apr;6(4):1433-9. (PMID: 17431122)
Thyroid. 2014 Nov;24(11):1618-24. (PMID: 25133449)
Lancet. 1979 Dec 22-29;2(8156-8157):1335-6. (PMID: 92676)
Front Oncol. 2014 Nov 04;4:309. (PMID: 25414832)
Thyroid. 2006 Dec;16(12):1229-42. (PMID: 17199433)
Cancer Causes Control. 2011 Mar;22(3):319-40. (PMID: 21203822)
Endocrinology. 2000 Jan;141(1):10-7. (PMID: 10614618)
J Histochem Cytochem. 2004 Jul;52(7):985-9. (PMID: 15208365)
Br J Cancer. 2007 Jul 2;97(1):123-8. (PMID: 17551495)
Int J Endocrinol. 2010;2010:805716. (PMID: 20016683)
Biochem Biophys Res Commun. 1993 Sep 30;195(3):1230-6. (PMID: 8216254)
Cancer Res. 2005 Sep 1;65(17):7917-25. (PMID: 16140963)
Thyroid. 2016 Mar;26(3):429-33. (PMID: 26739552)
Endocrinology. 2010 Jan;151(1):32-42. (PMID: 19906814)
المشرفين على المادة: 1406-16-2 (Vitamin D)
9002-71-5 (Thyrotropin)
A288AR3C9H (25-hydroxyvitamin D)
تواريخ الأحداث: Date Created: 20161014 Date Completed: 20170522 Latest Revision: 20190221
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC5063319
DOI: 10.1371/journal.pone.0164550
PMID: 27737011
قاعدة البيانات: MEDLINE
الوصف
تدمد:1932-6203
DOI:10.1371/journal.pone.0164550